SEC Form 4 · accession 0000914475-15-000024
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Charles Gorman
Officer — President and CEO · Director
Period of report
Jan 12, 2015
Accepted (ET)
Jan 13, 2015 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 12, 2015 | S | 3,750 | $28.43 | D | 184,702 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of 3,750 shares of common stock issued upon vesting of 7,500 restricted stock units on January 12, 2015 to cover payroll and withholding taxes, with the balance of the shares (3,750) maintained by the Reporting Person; the sale was affected by a broker pursuant to instructions set forth in a Rule 10b5-1 plan adopted by the Reporting Person and delivered to the broker on May 28, 2013.
- F2Represents a weighted average sales price per share. The prices actually received ranged from $27.31 to $29.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.